- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01155349
Brain Fitness in Parkinson's Disease
December 7, 2012 updated by: Jerri D. Edwards, University of South Florida
Cognitive Speed of Processing Training Among Persons With Parkinson's Disease
The purpose of this study is to examine the feasibility and potential effectiveness of a cognitive training program among persons with Parkinson's disease.
It is hypothesized that individuals with PD will be able to complete and benefit from the intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Parkinson's Disease (PD) affects about 1 million individuals in the United States.
In addition to the typical motor dysfunction, PD also affects cognition and vision, even in early stages of the disease, impairing instrumental activities of daily living such as driving.
Reduced cognitive speed of processing, or bradyphrenia, strongly contributes to cognitive decline in PD.
Recent research has demonstrated that interventions can enhance cognitive speed of processing, protect against further cognitive decline, and improve the everyday functioning of relatively healthy, older adults.
However, the potential of such training techniques to enhance cognitive functions among subpopulations with different disease states, such as PD, has not been thoroughly investigated.
The proposed study will further examine the feasibility and test the efficacy of a well-established cognitive training tool among individuals in the early stages of PD who have not been diagnosed with dementia.
A variety of factors have been found to influence cognitive performance among persons with PD and may moderate their ability to benefit from cognitive training such as age at disease onset, disease duration, manifestation, severity, and medication use as well as concomitant depression.
These factors along with demographic variables will be evaluated as moderators of training benefit.
Baseline cognitive assessments will be completed among seventy-five individuals with PD who will be randomized to cognitive training or a treatment-delayed control condition.
The efficacy of training to immediately enhance cognitive functioning will be evaluated through a post-training (or equivalent delay) assessment.
Disease and demographic factors that may impact the efficacy of cognitive training for persons with PD will be examined in relation to training gains.
Considering that cognitive function among individuals with PD is a strong predictor of everyday functioning and subsequent need for long term care, enhancing cognitive function of individuals with PD through training has great potential to prolong such persons' productivity, independence, and quality of life.
The information gained from this study will be useful for identifying individuals with PD who are most likely to benefit from cognitive training as well as the development, refinement, and implementation of appropriate cognitive interventions for this population.
Study Type
Interventional
Enrollment (Actual)
87
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33620
- University of South Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Criteria will be age 40 years or older and clinical diagnosis of idiopathic PD in Hoehn and Yahr stages 1 to 3, and on a stable medication regimen (no expected changes in next six months). Subjects with random or severe motor fluctuations and dyskinesias will be excluded. Further inclusion criteria will be no diagnosis of dementia nor evidence of severe dementia that may limit ability to benefit from training, and adequate visual acuity to view testing and training stimuli (far visual acuity >= 20/80).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: InSight Brain Fitness
|
A cognitive intervention designed to enhance speed of visual processing.
|
|
Placebo Comparator: No contact-control
|
No contact-control group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Useful Field of View
Time Frame: 3 and 6 months
|
A measure of visual processing speed independent of motor speed.
|
3 and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depressive Symptoms
Time Frame: 3 and 6 months
|
GDS and CES-D
|
3 and 6 months
|
|
CSRQ
Time Frame: 3 and 6 months
|
Quality of Life measure
|
3 and 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jerri D Edwards, Ph.D., University of South Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
May 1, 2012
Study Registration Dates
First Submitted
June 29, 2010
First Submitted That Met QC Criteria
June 29, 2010
First Posted (Estimate)
July 1, 2010
Study Record Updates
Last Update Posted (Estimate)
December 10, 2012
Last Update Submitted That Met QC Criteria
December 7, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- USF105832
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
EicOsis Human Health Inc.University of California, Davis; Michael J. Fox Foundation for Parkinson's...RecruitingParkinson's Disease (PD)United States
-
University of Kansas Medical CenterNot yet recruitingParkinson's Disease (PD)United States
-
AbbVieRecruiting
-
University Hospital Schleswig-HolsteinUniversity of Kiel; University of Cologne; University Hospital, Bonn; Philipps...Not yet recruitingParkinson's Disease (PD)
-
InvicroMerck Sharp & Dohme LLCRecruitingParkinson's Disease | Parkinson's Disease (PD) | Parkinson's Disease (Disorder)United States
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Guangzhou Henovcom Bioscience Co. Ltd.Frontage Clinical Services, Inc.Active, not recruitingParkinson's Disease (PD)United States
-
Universitätsklinikum Hamburg-EppendorfUniversity of TwenteRecruitingParkinson's Disease | Deep Brain StimulationGermany
-
Mission TherapeuticsMichael J. Fox Foundation for Parkinson's Research; Parkinson's UKRecruitingParkinson's Disease (PD) | Early Stage Parkinson's Disease | Mild to Moderate Parkinson's DiseaseUnited Kingdom
Clinical Trials on InSight
-
DascenaNot yet recruitingSepsis | Septic Shock | Severe Sepsis
-
Moravian UniversityCompleted
-
DascenaUniversity of California, San FranciscoWithdrawnSepsis | Septic Shock | Severe Sepsis
-
EyeQue Corp.Eye Boutique OptometryCompletedVisual AcuityUnited States
-
Centre Hospitalier EsquirolCompleted
-
Lunit Inc.King's College London; The Leeds Teaching Hospitals NHS TrustNot yet recruitingBreast Cancer | Breast DiseasesUnited Kingdom
-
Virginia Polytechnic Institute and State UniversityRiverain TechnologiesCompletedLung CancerUnited States
-
University of California, San FranciscoNational Institutes of Health (NIH); National Library of Medicine (NLM)Active, not recruiting
-
Linkoeping UniversityCompletedDepressive Symptoms | Childhood Cancer | Anxiety Disorders and Symptoms | Mental Health IssueSweden